
    
      This is a multicenter, open-label study designed to evaluate the safety, tolerability and
      efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo.
      Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo
      effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower
      eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic
      positioning device for photography) with at least one area of the face with normal
      pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%,
      BID for 24 weeks.
    
  